Asep Medical Holdings Inc. Achieves Significant Milestones Addressing Antibiotic Failure Through Proprietary Diagnostic & Therapeutic Technologies – Yahoo Finance

VANCOUVER, BC, Dec. 23, 2022 /PRNewswire/ – Asep Medical Holdings Inc. (“Asep Inc.” or the “Company”) (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is pleased to announce that, through its subsidiaries Sepset Biosciences Inc. (“Sepset“) and ABT Innovations Inc. (“ABT”), the Company is addressing antibiotic failure on two fronts — a novel diagnostic assay that detects severe sepsis in the emergency room (ER), and a peptide technology that combats hard-to-treat infections known as biofilms.
Antibiotic failure is generally referred to as any situation where bacteria survive antibiotic treatment, and the clinical symptoms of the infection persist¹. With around 47-50 million sepsis cases per year worldwide² and over 11 million deaths, faster and more accurate sepsis detection will save lives. In addition, there are currently no approved treatments for biofilm infections, which is alarming since 65%³ of all infections are biofilms.
Asep Inc.’s diagnostic technology, Sepset^{ER TM}, is a blood-based gene expression assay that can provide an early and accurate diagnosis of severe incidences of the deadly disease sepsis. Sepset^ER delivers results between 60-90 minutes whereas the conventional diagnostic tools may take approximately 8 – 36 hours. Early detection of sepsis along with timely, appropriate treatments increases the probability of survival for patients⁴ significantly.
In addition to speeding up the process of sepsis detection, Asep Inc. also offers a patented peptide technology that targets and suppresses biofilm regrowth and reduces inflammation, addressing the ineffectiveness of current treatments for a wide range of hard-to-treat infections. The technology covers a broad range of therapeutic applications, including bacterial biofilm infections (medical device infections, chronic infections, lung, bladder, wound, dental, skin, ear-nose and throat, sinusitis, orthopaedic, etc.), anti-inflammatories, anti-infective immune-modulators and vaccine adjuvants. This opens up a number of different potential paths to revenue generation for this ground-breaking technology.
To date, the Company and its subsidiaries have received over $20 million in non-dilutive grant funding from organizations, such as the Bill & Melinda Gates Foundation, Genome Canada and the University of British Columbia. The Company, through its pre-clinical partner iFyber LLC, has also received funding from the US Army for its novel antibiofilm peptide technology.
“Asep is addressing an unmet need in health care, which affects 49 million people per year. Having developed two new revolutionary technologies to diagnose sepsis and treat biofilm infection, the potential market opportunity for this company is massive as hospitals and clinics globally could be in line to treat their patients using these cutting-edge technologies,” stated Dr. Robert E. W. Hancock, the founder, chairman and CEO of Asep Inc.
ABOUT ASEP MEDICAL HOLDINGS INC.
Asep Medical Inc. (asepmedical.com) is dedicated to addressing antibiotic failure by developing novel solutions for significant unmet medical needs. The Company is a consolidation of two existing private companies (Sepset Biosciences Inc. and ABT Innovations Inc.) that are both in the advanced development of both proprietary diagnostic tools, enabling the early and timely identification of severe sepsis as well as broad-spectrum therapeutic agents to address multidrug-resistant biofilm infections.
Sepset Biosciences Inc. (sepset.ca) is developing a diagnostic technology that involves a patient gene expression signature that predicts severe sepsis, one of the significant diseases leading to antibiotic failure since antibiotics are the primary treatment for sepsis. Despite this, sepsis is responsible for nearly 20% of all deaths on the planet. The Sepset^ER test is a blood-based gene expression assay that is straightforward to implement, and results are obtained in about an hour in the emergency room or intensive care unit. This proprietary diagnostic technology differs from current diagnostic tests in enabling diagnosis of severe sepsis within 1-2 hours of first clinical presentation (i.e., in the emergency room), while other diagnostics only provide diagnosis after 24-36 hours. Asep Inc. believes this will enable critical early decisions to be made by physicians regarding appropriate therapies and reduce overall morbidity and mortality due to sepsis.
ABT Innovations Inc.’s (abtinnovations.ca) peptide technology covers a broad range of therapeutic applications, including bacterial biofilm infections (medical device infections, chronic infections, lung, bladder, wound, dental, skin, ear-nose and throat, sinusitis, orthopaedic, etc.), anti-inflammatories, anti-infective immune-modulators and vaccine adjuvants. The company is in the pre-clinical development phase with promising data.
FORWARD-LOOKING STATEMENTS —
This news release contains certain “forward-looking statements” within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as “anticipates,” “plan,” “continue,” “expect,” “project,” “intend,” “believe,” “anticipate,” “estimate,” “may,” “will,” “potential,” “proposed,” “positioned” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements include but are not limited to the successful clinical testing of our Sepsis diagnostic test and its intended filing for regulatory approval; and the undertaking of pre-clinical studies on our lead therapeutic, with the expectation that this will lead to fast-track clinical trials. Various assumptions were used in drawing conclusions or making the predictions contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks (including those risk factors identified in the Asep Medical Inc.’s prospectus dated November 9, 2021) available for review under the Company’s profile at www.sedar.com and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Asep Medical Inc. is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
_________________________
¹ https://www.frontiersin.org/articles/10.3389/fddsv.2022.892975/full#:~:text=Antibiotic%20failure%20can%20be%20defined%20as%20any%20situation%20where%20bacteria,symptoms%20of%20the%20infection%20persist.
² https://www.global-sepsis-alliance.org/sepsis
³ https://www.sciencedirect.com/science/article/pii/S1726490117302587
⁴ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6304323/#:~:text=However%2C%20early%20detection%20of%20sepsis,and%20a%20reduction%20in%20mortality.
View original content to download multimedia:https://www.prnewswire.com/news-releases/asep-medical-holdings-inc-achieves-significant-milestones-addressing-antibiotic-failure-through-proprietary-diagnostic–therapeutic-technologies-301709775.html
SOURCE ASEP Medical Holdings Inc.
Related Quotes
It's a scary time to be an investor, with the markets languishing and the threat of additional interest rate hikes next year weighing on stock prices. In this environment, it is important to control risk and one way to do that is by investing in quality healthcare companies with consistent, sustainable dividends. Cardinal Health's stock is up more than 60% over the past year.
For these companies' shareholders, it may be tempting to take profits right now. But both stocks can keep growing for a while.
The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
Until the pandemic hit, Wall Street largely ignored the vaccine market. This year will show there’s more to jabs than fighting Covid-19.
Telemedicine companies that represent a growing segment of the health care sector are seeing a surge in popularity both from investors and consumers.
It's been a wild 12 months for biotech company Bluebird Bio (NASDAQ: BLUE). Bluebird earned approval from the U.S. Food and Drug Administration (FDA) for Zynteglo and Skysona in August and September, respectively.
Medicare is designed to help eligible individuals pay for healthcare. One of the most important decisions to make when enrolling for the first time or making changes to your coverage during open enrollment is whether to opt for Medicare Advantage … Continue reading → The post Medicare Open Enrollment Is Almost Closed: Medicare Advantage vs. Medicare appeared first on SmartAsset Blog.
Applied Molecular Transport Inc (NASDAQ: AMTI) announced topline Phase 2 results from the LOMBARD monotherapy trial for AMT-101 in biologic-naïve and experienced patients with moderate-to-severe ulcerative colitis (UC). The clinical remission (CR) rate in patients treated with AMT-101 monotherapy was 17.1% (12/70 patients) compared to a CR rate of 20.0% (7/35 patients) with placebo, which was above the company's baseline assumption for placebo CR rates based on published data in moderate-to-seve
Mesoblast Limited (NASDAQ:MESO) Q1 2023 Earnings Call Transcript November 23, 2022 Dr. Silviu Itescu: Good morning, good afternoon to the operational highlights and financial results for the quarter ended September 30, 2022, as well as our upcoming Annual General Meeting. Apologies for the slight delay due to technical difficulties; beyond our control. Joining me here […]
Nearly three years after it was first identified in China, the coronavirus is now spreading through the vast country. China’s unyielding “zero-COVID” approach, which aimed to isolate all infected people, bought it years to prepare for the disease. Predicting deaths has proven tricky throughout the pandemic, since it is influenced by varied factors and China presents an especially complicated case because of opaque information sharing.
Scientists discover the glass frog's "superpower" in its ability to pool blood to turn see-through.
Gummies are especially problematic for kids as they're made to look like candy.
The availability of FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for PEComa.
Estimates from China’s top health authority say that nearly 37 million people were infected with COVID-19 in a single day on Dec. 20, according to a Bloomberg report. The report added that it is also likely that 248 million people contracted the virus in the first 20 days of the month. According to Bloomberg, the…
Depression is a leading cause of disability worldwide. Thomas Barwick/Stone via Getty ImagesDepression is a costly and debilitating condition that profoundly influences a person’s quality of life. In 2020, more than 21 million adults in the U.S. reported having at least one major depressive episode in the previous year. Depression symptoms increased dramatically during the COVID-19 pandemic, and now affect nearly 1 in 3 American adults. There are also many disparities in access to depression tre
Gilead'ls (GILD) HIV franchise gets a boost with FDA's approval of twice-yearly HIV treatment Sunlenca for the treatment of HIV-1 infection in heavily treatment-experienced adults with multi-drug resistance.
BEIJING — The hearses bearing black and yellow funeral paper flowers crept in a steady stream toward the Dongjiao crematory in eastern Beijing. Several dozen people crowded around the closed gate waiting to be let in. A man unable to get a spot in line could only watch, wondering what to do with the body of a relative who had just died of COVID-19. The hospital could not keep the body — there were already too many in its morgue. When he called the crematory, an employee told him he had to wait a
The United States has officially recorded more than 100 million COVID-19 cases. According to data from the Centers for Disease Control and Prevention updated late Thursday, the U.S. hit the milestone as of Dec. 21. This makes America the first nation to report total cases in the nine-figure range, data from Johns Hopkins Coronavirus Resource Center shows.
According to a large study, dubbed PANORAMIC, Merck & Co Inc's (NYSE: MRK) COVID-19 antiviral molnupiravir speeds up recovery but does not reduce the hospitalization or death rate in higher-risk vaccinated adults. The study was conducted when the Omicron variant was dominant and compared the oral pill against standard treatment alone in people over 50 or those aged 18 and older with underlying conditions. When Merck initially tested molnupiravir, it was 30% effective in reducing hospitalizations
Christina Haack is updating her followers on her health, revealing the results from a recent scan. Keep reading to find out how she’s dealing with her mercury and lead poisoning diagnoses.

source